Jpmorgan Chase & CO Dexcom Inc Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Dexcom Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,341,379 shares of DXCM stock, worth $384 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

4,341,379

Previous 5,550,308 21.78%

Holding current value

$384 Million

Previous $372 Million 9.23%

% of portfolio

0.03%

Previous 0.03%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$65.68 - $81.01 $79.4 Million - $97.9 Million	-1,208,929 Reduced 21.78%	4,341,379 $338 Million
Q3 2024 Dec 26, 2024	SELL	$64.0 - $116.06 $74.3 Million - $135 Million	-1,160,675 Reduced 17.3%	5,550,308 $372 Million
Q3 2024 Nov 08, 2024	SELL	$64.0 - $116.06 $72.4 Million - $131 Million	-1,131,654 Reduced 16.94%	5,550,308 $372 Million
Q2 2024 Dec 26, 2024	BUY	$110.31 - $140.45 $128 Million - $163 Million	1,160,675 Added 20.91%	6,710,983 $761 Million
Q2 2024 Aug 12, 2024	BUY	$110.31 - $140.45 $109 Million - $138 Million	985,366 Added 17.3%	6,681,962 $758 Million
Q1 2024 Dec 26, 2024	BUY	$114.22 - $140.1 $16.7 Million - $20.5 Million	146,288 Added 2.64%	5,696,596 $790 Million
Q1 2024 May 10, 2024	BUY	$114.22 - $140.1 $5.02 Million - $6.16 Million	43,977 Added 0.78%	5,696,596 $790 Million
Q4 2023 Dec 26, 2024	BUY	$75.49 - $124.16 $7.72 Million - $12.7 Million	102,311 Added 1.84%	5,652,619 $701 Million
Q4 2023 Feb 12, 2024	BUY	$75.49 - $124.16 $18.3 Million - $30.1 Million	242,352 Added 4.48%	5,652,619 $701 Million
Q3 2023 Nov 14, 2023	SELL	$86.06 - $137.93 $625 Million - $1 Billion	-7,262,910 Reduced 57.31%	5,410,267 $505 Million
Q2 2023 Aug 11, 2023	BUY	$112.47 - $130.98 $215 Million - $250 Million	1,908,349 Added 17.73%	12,673,177 $1.63 Billion
Q1 2023 May 18, 2023	BUY	$104.0 - $122.92 $18.9 Million - $22.4 Million	181,849 Added 1.72%	10,764,828 $1.25 Billion
Q1 2023 May 11, 2023	SELL	$104.0 - $122.92 $6.67 Million - $7.88 Million	-64,117 Reduced 0.6%	10,582,979 $1.23 Billion
Q4 2022 Feb 13, 2023	BUY	$84.98 - $122.67 $33.9 Million - $49 Million	399,056 Added 3.89%	10,647,096 $1.21 Billion
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $10.3 Million - $12.8 Million	-135,409 Reduced 1.3%	10,248,040 $825 Million
Q2 2022 Aug 11, 2022	BUY	$67.99 - $132.89 $513 Million - $1 Billion	7,543,026 Added 265.56%	10,383,449 $774 Million
Q1 2022 May 11, 2022	SELL	$94.08 - $130.2 $8.71 Million - $12.1 Million	-92,607 Reduced 3.16%	2,840,423 $1.45 Billion
Q4 2021 Feb 10, 2022	SELL	$129.87 - $162.82 $7.83 Million - $9.81 Million	-60,255 Reduced 2.01%	2,933,030 $1.57 Billion
Q3 2021 Nov 12, 2021	BUY	$106.71 - $143.18 $319 Million - $429 Million	2,993,285 New	2,993,285 $1.64 Billion

Others Institutions Holding DXCM

# of Institutions

1,085

Shares Held

352M

Call Options Held

8.45M

Put Options Held

5.75M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $34.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Dexcom Inc Transaction History